Miscellaneous Neoplasms

  • Robin P. Boushey
  • Husein Moloo


While adenomas and adenocarcinoma account for the ­majority of colorectal neoplasms, several other less frequent types of malignancy can occur, which can often present as diagnostic and therapeutic challenges to the clinician. These tumors can be classified based on their tissue of origin and include epithelial, mesenchymal, neural, vascular, or lymphoid tumors.



This chapter was authored by ­Richard Devine and Marc Brand in the previous edition of this ­textbook.


  1. 1.
    Kulke MH, Mayer RJ. Carcinoid tumours. N Engl J Med. 1999;340:858–68.PubMedGoogle Scholar
  2. 2.
    Ganim RB, Norton JA. Recent advances in carcinoid pathogenesis, diagnosis and management. Surg Oncol. 2000;9:173–9.PubMedGoogle Scholar
  3. 3.
    Eriksson B, Oberg K, Stridsberg M. Tumour markers in neuroendocrine tumours. Digestion. 2000;62:33–8.PubMedGoogle Scholar
  4. 4.
    Lucas KJ, Feldman JM. Flushing in the carcinoid syndrome and plasma kallikrein. Cancer. 1986;58:2290–3.PubMedGoogle Scholar
  5. 5.
    Reubi JC, Laissue J, Waser B. Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci. 1994;733:122–37.PubMedGoogle Scholar
  6. 6.
    Rea F, Binda R, Spreafico G. Bronchial carcinoids: a review of 60 patients. Ann Thorac Surg. 1989;47:412–4.PubMedGoogle Scholar
  7. 7.
    Schreurs AJ, Westermann CJ, van den Bosch JM. A twenty-five-year follow-up of ninety-three resected typical carcinoid tumours of the lung. J Thorac Cardiovasc Surg. 1992;104:1470–5.PubMedGoogle Scholar
  8. 8.
    Barclay TH, Schapira DV. Malignant tumours of the small intestine. Cancer. 1983;51:878–81.PubMedGoogle Scholar
  9. 9.
    Makridis C, Oberg K, Juhlin C. Surgical treatment of mid-gut carcinoid tumors. World J Surg. 1990;14:377–83.PubMedGoogle Scholar
  10. 10.
    Moertel CG, Dockerty MB, Judd ES. Carcinoid tumors of the vermiform appendix. Cancer. 1968;21:270–8.PubMedGoogle Scholar
  11. 11.
    Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med. 1987;317:1699–701.PubMedGoogle Scholar
  12. 12.
    Berardi RS. Carcinoid tumors of the colon (exclusive of the rectum): review of the literature. Dis Colon Rectum. 1972;15:383–91.PubMedGoogle Scholar
  13. 13.
    Jetmore AB, Ray JE, Gathright Jr JB. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum. 1992;35:717–25.PubMedGoogle Scholar
  14. 14.
    Naunheim KS, Zeitels J, Kaplan EL. Rectal carcinoid tumors – treatment and prognosis. Surgery. 1983;94:670–6.PubMedGoogle Scholar
  15. 15.
    Burke M, Shepherd N, Mann CV. Carcinoid tumours of the rectum and anus. Br J Surg. 1987;74:358–61.PubMedGoogle Scholar
  16. 16.
    Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol. 1999;10:S31–8.PubMedGoogle Scholar
  17. 17.
    Kubota A, Yamada Y, Kagimoto S. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in the treatment of human endocrine tumors. J Clin Invest. 1994;93:1321–5.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Kvols LK, Moertel CG, O’Connell MJ. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315:663–6.PubMedGoogle Scholar
  19. 19.
    Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment Pharmacol Ther. 2000;14:557–60.PubMedGoogle Scholar
  20. 20.
    O’Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88:770–6.PubMedGoogle Scholar
  21. 21.
    Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, et al. Octreotide acetate long-acting formulation ­versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol. 1999;17:600–6.PubMedGoogle Scholar
  22. 22.
    Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials. 1979;2(4):327–34.PubMedGoogle Scholar
  23. 23.
    Engstrom PF, Lavin PT, Moertel CG, Folsch E, Douglass Jr HO. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol. 1984;2(11):1255–9.PubMedGoogle Scholar
  24. 24.
    Bukowski RM, Johnson KG, Peterson RF, Stephens RL, Rivkin SE, Neilan B, et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer. 1987;60(12):2891–5.PubMedGoogle Scholar
  25. 25.
    Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68(2):227–32.PubMedGoogle Scholar
  26. 26.
    Moertel CG, Johnson CM, McKusick MA, Martin Jr JK, Nagorney DM, Kvols LK, et al. The management of patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med. 1994;120(4):302–9.PubMedGoogle Scholar
  27. 27.
    Schupak KD, Wallner KE. The role of radiation therapy in the treatment of locally unresectable or metastatic carcinoid tumors. Int J Radiat Oncol Biol Phys. 1991;20(3):489–95.PubMedGoogle Scholar
  28. 28.
    Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002;32(2):148–55.PubMedGoogle Scholar
  29. 29.
    Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer. 2004;11(1):1–18.PubMedGoogle Scholar
  30. 30.
    Rengtgen DS, Thompson W, Garbutt J, Seigler HF. Radiologic, endoscopic and surgical considerations of melanoma metastatic to the GI tract. Surgery. 1984;95:635–9.Google Scholar
  31. 31.
    Malik A, Hull TL, Floruta C. What is the best surgical treatment for anorectal melanoma? Int J Colorectal Dis. 2004;19(2):121–3.PubMedGoogle Scholar
  32. 32.
    Tessier DJ, McConnell EJ, Young-Fadok T, Wolff BG. Melanoma metastatic to the colon: case series and review of the literature with outcome analysis. Dis Colon Rectum. 2003;46(4):441–7.PubMedGoogle Scholar
  33. 33.
    Ollila DW, Essner R, Wanek LA, Morton DL. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg. 1996;131:975–9.PubMedGoogle Scholar
  34. 34.
    Allen PJ, Cott DG. The surgical management of metastatic melanoma. Ann Surg Oncol. 2002;9(8):762–70.PubMedGoogle Scholar
  35. 35.
    Schuchter LM, Green R, Fraker D. Primary and metastatic diseases in malignant melanoma of the gastrointestinal tract. Curr Opin Oncol. 2000;12:181–5.PubMedGoogle Scholar
  36. 36.
    Kawashima A, Fishman EK, Kuhlman JE, Schuchter LM. CT of malignant melanoma: patterns of small bowel and mesenteric involvement. J Comput Assist Tomogr. 1991;15:570–1.PubMedGoogle Scholar
  37. 37.
    Damian DL, Fulham MJ, Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res. 1996;6:325–9.PubMedGoogle Scholar
  38. 38.
    Buzaid AC, Sandler AB, Mani S, Curtis AM, Poo WJ, Bolognia JL, et al. Role of computed tomography in the staging of primary melanoma. J Clin Oncol. 1993;11:638–43.PubMedGoogle Scholar
  39. 39.
    Agrawal S, Yao TJ, Coit DG. Surgery for melanoma metastatic to the gastrointestinal tract. Ann Surg Oncol. 1999;6:636–44.Google Scholar
  40. 40.
    Khadra MH, Thompson JF, Milton GW, McCarthy WH. The justification for surgical treatment of metastatic melanoma of the gastrointestinal tract. Surg Gynecol Obstet. 1990;171:413–6.PubMedGoogle Scholar
  41. 41.
    Ricaniadis N, Konstandoulakis MM, Walsh D, Karakousis CP. Gastrointestinal metastases from malignant melanoma. Surg Oncol. 1995;4:105–10.PubMedGoogle Scholar
  42. 42.
    Clemmensen OJ, Fenger C. Melanoctyes in the anal canal ­epithelium. Histopathology. 1991;18:237–41.PubMedGoogle Scholar
  43. 43.
    Avital S, Romaguera RL, Sands L, Marchetti F, Hellinger MD. Primary malignant melanoma of the right colon. Am Surg. 2004;70:649–51.PubMedGoogle Scholar
  44. 44.
    Sarah P, MaNiff JF, Madison MD, Wen-Jen Poo H, Bayar S, Sallem RR. Colonic melanoma, primary or regressed primary. J Clinic Gastroenterol. 2000;30:440–4.Google Scholar
  45. 45.
    Gervasoni Jr JE, Wanebo HJ. Cancers of the anal canal and anal margin. Cancer Invest. 2003;21(3):452–64.PubMedGoogle Scholar
  46. 46.
    Blecker D, Abraham S, Furth EE, Kochman ML. Melanoma of the gastrointestinal tract. Am J Gastroenterol. 1999;94(12):3427–33.PubMedGoogle Scholar
  47. 47.
    Wanebo HJ, Woodruff JM, Farr GH, Quan SH. Anorectal melanomas. Cancer. 1981;47:1891–5.PubMedGoogle Scholar
  48. 48.
    Brady MS, Kavolius JP, Quan SH. Anorectal melanoma. A 64-year experience at Memorial Sloan-Kettering Cancer ­Center. Dis Colon Rectum. 1995;38(2):146–51.PubMedGoogle Scholar
  49. 49.
    Billingsley KG, Stern LE, Lowy AM, Kahlenberg MS, Thomas Jr CR. Uncommon anal neoplasms. Surg Oncol Clin N Am. 2004;13(2):375–88.PubMedGoogle Scholar
  50. 50.
    Yeh JJ, Shia J, Hwu WJ, Busam KJ, Paty PB, Guillem JG, et al. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg. 2006;244(6):1012–7.PubMedPubMedCentralGoogle Scholar
  51. 51.
    Belli F, Gallino GF, Lo Vullo S, Mariani L, Poiasina E, Leo E. Melanoma of the anorectal region. The experience of the National Cancer Institute of Milano. Eur J Surg Oncol. 2009;35(7):757–62.PubMedGoogle Scholar
  52. 52.
    Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol. 2002;20(7):1818–25.PubMedGoogle Scholar
  53. 53.
    Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N. Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma. Cancer. 2006;106(7):1431–42.PubMedGoogle Scholar
  54. 54.
    Kawano N, Tashiro M, Taguchi M, Kihara Y, Yoshikawa I, Syukuwa K, et al. Combined treatment with dacarbazine, nimustine, cisplatin, and tamoxifen plus interferon-beta in a patient with advanced anorectal malignant melanoma. Nippon Shokakibyo Gakkai Zasshi. 2008;105(11):1627–33.PubMedGoogle Scholar
  55. 55.
    Quintas-Cardama A, Lazar AJ, Woodman SE, Kim K, Ross M, Hwu P, et al. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol. 2008;5(12):737–40.PubMedGoogle Scholar
  56. 56.
    Mazur MT, Clark HB. Gastric Stromal tumors: reappraisal of histogenesis. Am J Surg Pathol. 1983;7:507–19.PubMedGoogle Scholar
  57. 57.
    Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain of function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.PubMedGoogle Scholar
  58. 58.
    Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607):708–10.PubMedGoogle Scholar
  59. 59.
    Biasco G, Velo D, Angriman I, Astorino M, Baldan A, Baseggio M, et al. Gastrointestinal stromal tumors: report of an audit and review of the literature. Eur J Cancer Prev. 2009;18(2):106–16.PubMedGoogle Scholar
  60. 60.
    Steigen SE, Eide TJ. Gastrointestinal stromal tumors (GISTs): a review. APMIS. 2009;117:73–86.PubMedGoogle Scholar
  61. 61.
    Tryggvason G, Gisalason HG, Magnusson MK, Jonasson JG. Gastrointestinal stromal tumors in Iceland, 1990–2003: the Icelandic GIST study, a population based incidence and pathologic risk stratification study. Int J Cancer. 2005;117:289–93.PubMedGoogle Scholar
  62. 62.
    Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long term follow up and review of the literature. Am J Surg Pathol. 2005;29:1373–81.PubMedGoogle Scholar
  63. 63.
    Kingham TP, DeMatteo RP. Multidisciplinary treatment of gastrointestinal stromal tumors. Surg Clin N Am. 2009;89:217–33.PubMedGoogle Scholar
  64. 64.
    Diment J, Tamborini E, Casali P, Gronchi A, Carney JA, Colecchia M. Carney triad: case report and molecular analysis of gastric tumor. Hum Pathol. 2005;36:112–6.PubMedGoogle Scholar
  65. 65.
    Matyakhina L, Bei TA, McWhinney SR, Pasini B, Cameron S, Gunawan B, et al. Genetics of Carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J Clin Endocrinol Metab. 2007;92:3728–32.PubMedGoogle Scholar
  66. 66.
    Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol. 2006;30(1):90–6.PubMedGoogle Scholar
  67. 67.
    Takazawa Y, Sakurai S, Sakuma Y, Ikeda T, Yamaguchi J, Hashizume Y, et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen’s disease). Am J Surg Pathol. 2005;29(6):755–63.PubMedGoogle Scholar
  68. 68.
    Agaimy A, Wünsch PH, Hofstaedter F, Blaszyk H, Rümmele P, Gaumann A, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol. 2007;31(1):113–20.PubMedGoogle Scholar
  69. 69.
    Nilsson B, Bümming P, Meis-Kindblom JM, Odén A, Dortok A, Gustavsson B, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era – a population-based study in western Sweden. Cancer. 2005;103(4):821–9.PubMedGoogle Scholar
  70. 70.
    Ueyama T, Guo KJ, Hashimoto H, Daimaru Y, Enjoji M. A clinicopathologic and immunohistochemical study of gastrointestinal stromal tumors. Cancer. 1992;69:947–55.PubMedGoogle Scholar
  71. 71.
    Sandrasegaran K, Rajesh A, Rushing DA, Rydberg J, Akisik FM, Henley JD. Gastrointestinal stromal tumors: CT and MRI findings. Eur Radiol. 2005;15(7):1407–14.PubMedGoogle Scholar
  72. 72.
    Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130(10):1466–78.PubMedGoogle Scholar
  73. 73.
    Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32(2):153–62.PubMedGoogle Scholar
  74. 74.
    Rader AE, Avery A, Wait CL, McGreevey LS, Faigel D, ­Heinrich MC. Fine-needle aspiration biopsy diagnosis of gastrointestinal stromal tumors using morphology, immunocytochemistry, and mutational analysis of c-kit. Cancer. 2001;93:269–75.PubMedGoogle Scholar
  75. 75.
    Stelow EB, Stanley MW, Mallery S, Lai R, Linzie BM, Bardales RH. Endoscopic ultrasound guided fine needle aspiration findings of gastrointestinal leiomyomas and gastrointestinal stromal tumors. Am J Clin Pathol. 2003;119:703–8.PubMedGoogle Scholar
  76. 76.
    DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8.PubMedPubMedCentralGoogle Scholar
  77. 77.
    Novitsky YW, Kercher KW, Sing RF, Heniford BT. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg. 2006;243:738–45.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Eisenberg BL, Judson I. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol. 2004;11:465–75.PubMedGoogle Scholar
  79. 79.
    Yeh C, Chen H, Tang R, Tasi W, Lin P, Wang J. Surgical outcome after surgical resection of rectal leiomyosarcoma. Dis Colon Rectum. 2000;43:1517–21.PubMedGoogle Scholar
  80. 80.
    van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358(9291):1421–3.PubMedGoogle Scholar
  81. 81.
    Gold JS, DeMatteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg. 2006;244:176–84.PubMedPubMedCentralGoogle Scholar
  82. 82.
    dos Santos Fernandes G, Blanke CD, Freitas D, Guedes R, Hoff PM. Perioperative treatment of gastrointestinal stromal tumors. Oncology. 2009;23(1):54–61.Google Scholar
  83. 83.
    Malhotra P, Singh M, Kochhar R, Nada R, Wig JD, Varma N, et al. Leukemia infiltration of bowel in chronic lymphocytic leukemia. Gastrointest Endosc. 2005;62(4):614–5.PubMedGoogle Scholar
  84. 84.
    Heiberg E, Wolverson M, Sandaram M, Sheilds JB. CT findings in leukemia. AJR Am J Roentgenol. 1984;143:1317–23.PubMedGoogle Scholar
  85. 85.
    Salek J, Sideridis K, White S. Chronic lymphocytic leukemia of the intestinal tract. Gastrointest Endosc. 2006;63(7):1072–3.PubMedGoogle Scholar
  86. 86.
    Hunter T, Bjelland JC. Gastrointestinal complications of leukemia and its treatment. AJR Am J Roentgenol. 1984;142:513–8.PubMedGoogle Scholar
  87. 87.
    Gavan DR, Hendry GM. Colonic complications of acute lymphoblastic leukemia. Br J Radiol. 1994;67:449–52.PubMedGoogle Scholar
  88. 88.
    Sloas MM, Flynn PM, Kaste SC, Patrick CC. Typhlitis in children with cancer: a 30 year experience. Clin Infect Dis. 1993;17:484–90.PubMedGoogle Scholar
  89. 89.
    Hayes Jr D, Leonardo JM. Neutropenic enterocolitis in a woman treated with 5-fluorouracil and leucovorin for colon carcinoma. NC Med J. 2002;63:132–4.Google Scholar
  90. 90.
    Avigan D, Richardson P, Elias A, Demetri G, Shapiro M, Schnipper L, et al. Neutropenic enterocolitis as a complication of high dose chemotherapy with stem cell rescue in patients with solid tumors: a case series with a review of the literature. Cancer. 1998;83(3):409–14.PubMedGoogle Scholar
  91. 91.
    Pestalozzi BC, Sotos GA, Choyke PL, Fisherman JS, Cowan KH, O’Shaughnessy JA. Typhlitis resulting from treatment with taxol and doxorubicin in patients with metastatic breast cancer. Cancer. 1993;71(5):1797–800.PubMedGoogle Scholar
  92. 92.
    Paulino AF, Kenney R, Forman EN, Medeiros LJ. Typhlitis in a patient with acute lymphoblastic leukemia prior to the administration of chemotherapy. Am J Pediatr Hematol Oncol. 1994;16:348–51.PubMedGoogle Scholar
  93. 93.
    Cunningham SC, Fakhry K, Bass BL, Napolitano LM. Neutropenic enterocolitis in adults: case series and review of the literature. Dig Dis Sci. 2005;50:215–20.PubMedGoogle Scholar
  94. 94.
    Kulaylat M, Doerr R, Ambrus J. A case presentation and review of neutropenic enterocolitis. J Med. 1997;28:1–19.PubMedGoogle Scholar
  95. 95.
    Hsu TF, Huang HH, Yen DH. ED presentation of neutropenic enterocolitis in adult patients with acute leukemia. Am J Emerg Med. 2004;22:276–9.PubMedGoogle Scholar
  96. 96.
    Ullery BW, Pieracci FM, Rodney JRM, Barie PS. Neutropenic enterocolitis. Surg Infect. 2009;10(3):307–14.Google Scholar
  97. 97.
    Davila ML. Neutropenic enterocolitis. Curr Opin Gastroenterol. 2006;22:44–7.PubMedGoogle Scholar
  98. 98.
    Gorshluter M, Ulrich M, Strehl J, Ziske C, Schepke M, Schmidt-Wolf IGH, et al. Neutropenic enterocolitis in adults: systematic analysis of evidence quality. Eur J Hematol. 2005;75:1–13.Google Scholar
  99. 99.
    Picardi M, Camera A, Pane F, Rotoli B. Improved management of neutropenic enterocolitis using early ultrasound scan and vigorous medical treatment. Clin Infect Dis. 2007;45:403–7.PubMedGoogle Scholar
  100. 100.
    Villar HV, Warneke JA, Peck MD, Durie B, Bjelland JC, Hunter TB. Role of surgical treatment in the management of complications of the gastrointestinal tract in patients with leukemia. Surg Gynecol Obstet. 1987;165(3):217–22.PubMedGoogle Scholar
  101. 101.
    Glenn J, Funkhouser WK, Schneider PS. Acute illnesses necessitating urgent abdominal surgery in neutropenic cancer patients: description of 14 cases and review of the literature. Surgery. 1989;105:778–9.PubMedGoogle Scholar
  102. 102.
    Quayle FJ, Lowney JK. Colorectal lymphoma. Clin Colon Rectal Surg. 2006;19:49–53.PubMedPubMedCentralGoogle Scholar
  103. 103.
    Koch P, del Valle F, Berdel WE, Willich NA, Reers B, ­Hiddemann W, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001;19(18):3861–73.PubMedGoogle Scholar
  104. 104.
    Zighelboim J, Larson MV. Primary colonic lymphoma, clinical presentation, histopathologic features and outcome with combination chemotherapy. J Clin Gastroenterol. 1994;18:291–7.PubMedGoogle Scholar
  105. 105.
    Dionigi G, Annoni M, Rovera F, Boni L, Villa F, Castano P, et al. Primary colorectal lymphomas: review of the literature. Surg Oncol. 2007;16 Suppl 1:S169–71.PubMedGoogle Scholar
  106. 106.
    Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumours of the gastrointestinal tract. Br J Surg. 1961;49:80–9.PubMedGoogle Scholar
  107. 107.
    Musallam K, Hatoum H, Barada K, Taher A, Salem ME, Malek EM, et al. Primary colorectal lymphoma. Med Oncol. 2010;27(2):249–54.PubMedGoogle Scholar
  108. 108.
    Wong MTC, Eu KW. Primary colorectal lymphomas. Colorectal Dis. 2006;8:586–91.PubMedGoogle Scholar
  109. 109.
    Lewin KJ, Ranchod M, Dorfmann RF. Lymphomas of the gastrointestinal tract – a study of 119 cases presenting with gastrointestinal disease. Cancer. 1978;43:693–707.Google Scholar
  110. 110.
    Contreary K, Nance FC, Becker WF. Primary lymphoma of the gastrointestinal tract. Ann Surg. 1980;191:593–8.PubMedPubMedCentralGoogle Scholar
  111. 111.
    Wychulis AR, Bears OH, Woolner LB. Malignant lymphoma of the colon – a study of 69 cases. Arch Surg. 1966;93:215–25.PubMedGoogle Scholar
  112. 112.
    Fan CW, Changchien CR, Wang JY, Chen JS, Hsu KC, Tang R, et al. Primary colorectal lymphoma. Dis Colon Rectum. 2000;43(9):1277–82.PubMedGoogle Scholar
  113. 113.
    Azab MB, Henry-Amar M, Rougier P, Bognel C, Theodore C, Carde P, et al. Prognostic factors in primary gastrointestinal non-Hodgkin’s lymphoma. A multivariate analysis, report of 106 cases, and review of the literature. Cancer. 1989;64(6):1208–17.PubMedGoogle Scholar
  114. 114.
    Jinnai D, Iwasa Z, Watanuki T. Malignant lymphoma of the large intestine – operative results in Japan. Surg Today. 1983;13:331–6.Google Scholar

Copyright information

© ASCRS (American Society of Colon and Rectal Surgeons) 2011

Authors and Affiliations

  • Robin P. Boushey
    • 1
  • Husein Moloo
    • 2
    • 3
  1. 1.General Surgery Research, Site Lead, Colorectal Cancer Program Champlain LHIN, Investigator, Ottawa Regional Cancer Center, Affiliate Investigator, Ottawa Hospital Research Institute, Department of SurgeryThe Ottawa Hospital – General CampusOttawaCanada
  2. 2.Ottawa Hospital Research InstituteUniversity of OttawaOttawaCanada
  3. 3.Department of SurgeryThe Ottawa HospitalOttawaCanada

Personalised recommendations